Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

@article{Feagan2017InductionTW,
  title={Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.},
  author={Brian G Feagan and W J Sandborn and G D'Haens and Juli{\'a}n Pan{\'e}s and Arthur Kaser and Marc Ferrante and Edouard J. Louis and Denis Franchimont and Olivier Dewit and Ursula Seidler and Kyung-Jo Kim and Markus F Neurath and Stefan Schreiber and Paul Scholl and Chandrasena Pamulapati and Bojan Lalovic and Sudha Visvanathan and Steven J. Padula and Ivona Herichova and Adina I Soaita and David B. Hall and Wulf Otto Boecher},
  journal={Lancet},
  year={2017},
  volume={389 10080},
  pages={1699-1709}
}
BACKGROUND The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease. METHODS In this randomised, double-blind, placebo-controlled phase 2 study, we enrolled patients at 36 referral sites in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 43 times over the past 90 days. VIEW TWEETS